8 completed, 1 recruiting, 1 unknown. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow Primary Open-Angle Glaucoma: new trials by email Literature Review of Primary Open-Angle Glaucoma trials Research Report on Primary Open-Angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
| An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert Bimatoprost - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 81 | 2015-08-10 | 2019-04-02 |
| Dose-Ranging Study of the Bimatoprost Ocular Insert Bimatoprost, Timolol 0.5%, Placebo Ocular Insert - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 156 | 2015-01-19 | 2020-06-04 |
| An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product Bimatoprost - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 75 | 2014-06-05 | 2019-02-26 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Subtenon administration of autologous ADRC, Liposuction, ADRC isolation - Retinal Degeneration, Primary Open-Angle Glaucoma | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 16 | 2014-05-01 | 2017-07-21 |
| Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Bimatoprost, Timolol 0.5%, Placebo Eye Drops - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | ForSight Vision5, Inc. | 169 | 2013-10-23 | 2018-04-20 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle - Primary Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Lexicon Pharmaceuticals | 63 | 2012-03-01 | 2015-09-14 |
| Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension OPA-6566, Placebo, Latanoprost - Primary Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Kubota Vision Inc. | 160 | 2011-09-01 | 2014-03-11 |
| Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3 - Ocular Hypertension, Primary Open-Angle Glaucoma | Phase 2 | Completed | Allergan | 163 | 2010-06-01 | 2014-08-05 |
| Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Pfizer | 318 | 2007-12-11 | 2021-04-30 |
Glaucoma, Open-Angle (10) · Ocular Hypertension (8) · Glaucoma (2) · Optic Atrophy (1) · Optic Nerve Diseases (1) · Optic Nerve Injuries (1) · Retinal Degeneration (1)
Eye Diseases (10) · Glaucoma (8) · Cranial Nerve Diseases (2) · Nervous System Diseases (2) · Ocular Hypertension (2) · Cranial Nerve Injuries (1) · Craniocerebral Trauma (1) · Eye Diseases, Hereditary (1) · Optic Nerve Diseases (1) · Retinal Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Bimatoprost (5) · Latanoprost (2) · LX-7101 (1) · Lipectomy (1) · PF 04217329 (1) · Timolol (1)
ForSight Vision5, Inc. (4) · Allergan (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · Kubota Vision Inc. (1) · Lexicon Pharmaceuticals (1) · Pfizer (1) · Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. (1)
United States (8) · China (1) · Russia (1)
Michelle Chen, PhD (4) · Alina K Drakon, MD (1) · Ilya I Eremin, MD, PhD (1) · Joel Freiman, M.D., MPH (1) · John W Chandler, MD (1) · Julia P Sotnikova, MD (1) · Yuanbo Liang (1)